Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SETH LERNER and ASHISH KAMAT.
SETH LERNER
Connection Strength
3.897
ASHISH KAMAT
  1. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2024 Dec 26.
    View in: PubMed
    Score: 0.249
  2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
    View in: PubMed
    Score: 0.245
  3. Bladder-sparing Therapy for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec; 86(6):516-527.
    View in: PubMed
    Score: 0.243
  4. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? Eur Urol Oncol. 2024 Jun; 7(3):412-420.
    View in: PubMed
    Score: 0.230
  5. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
    View in: PubMed
    Score: 0.228
  6. Reduced Dose Intravesical Bacillus Calmette-Gu?rin: Why It Might Not Matter. Bladder Cancer. 2022; 8(2):113-117.
    View in: PubMed
    Score: 0.208
  7. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
    View in: PubMed
    Score: 0.202
  8. The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.
    View in: PubMed
    Score: 0.189
  9. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 06; 3(3):318-340.
    View in: PubMed
    Score: 0.179
  10. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol. 2020 06; 77(6):669-670.
    View in: PubMed
    Score: 0.179
  11. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146.
    View in: PubMed
    Score: 0.149
  12. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
    View in: PubMed
    Score: 0.138
  13. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202.
    View in: PubMed
    Score: 0.136
  14. Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer. 2015 Mar 30; 1(1):29-30.
    View in: PubMed
    Score: 0.127
  15. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42.
    View in: PubMed
    Score: 0.090
  16. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2024 Dec 17.
    View in: PubMed
    Score: 0.062
  17. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2024 Aug 25.
    View in: PubMed
    Score: 0.061
  18. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.059
  19. Bacillus Calmette-Gu?rin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023 Oct 04; 24(1):636.
    View in: PubMed
    Score: 0.057
  20. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2023; 9(3):271-286.
    View in: PubMed
    Score: 0.057
  21. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul; 20(7):452.
    View in: PubMed
    Score: 0.056
  22. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 08; 84(2):176-190.
    View in: PubMed
    Score: 0.056
  23. Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
    View in: PubMed
    Score: 0.055
  24. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.050
  25. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46.
    View in: PubMed
    Score: 0.049
  26. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):442-450.
    View in: PubMed
    Score: 0.048
  27. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.047
  28. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.044
  29. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.044
  30. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.037
  31. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 09; 13(9):621-625.
    View in: PubMed
    Score: 0.037
  32. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 09; 198(3):552-559.
    View in: PubMed
    Score: 0.037
  33. Corrigendum to "Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort" [Eur Urol 2010;57:300-9]. Eur Urol. 2015 Jul; 68(1):171.
    View in: PubMed
    Score: 0.031
  34. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.030
  35. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7.
    View in: PubMed
    Score: 0.029
  36. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98.
    View in: PubMed
    Score: 0.029
  37. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9.
    View in: PubMed
    Score: 0.025
  38. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.024
  39. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.022
  40. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.022
  41. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.019
  42. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.